00:46 , May 11, 2019 |  BioCentury  |  Product Development

Now grown up, independent biotechs bulk up their platforms with more modalities

As the incoming class of independent biotechs look to build on their clinical and commercial successes, a handful are expanding beyond the technology that got them there, bringing in new modalities to complement their platforms...
17:53 , Aug 29, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cervical cancer; skin cancer Mouse studies suggest a vaccine based on a nanoparticle-HpV16gp2 peptide conjugate could help treat human papillomavirus (HPV)-associated cancers. The conjugate consists of nanoparticles with a polypropylene sulfide core and HpV16gp2...
22:48 , May 25, 2018 |  BC Extra  |  Company News

Management tracks: ISA, ImCheck, ArQule

Immunotherapy company ISA Pharmaceuticals B.V. (Leiden, the Netherlands) promoted CBO Gerben Moolhuizen to CEO, effective June 1. He succeeds CEO Ronald Loggers. Also in May, ISA hired Leon Hooftman as CMO. Hooftman was CMO at...
00:18 , Dec 22, 2017 |  BC Week In Review  |  Company News

Regeneron, ISA partner for HPV16-induced cancer combinations

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and ISA Pharmaceuticals B.V. (Leiden, the Netherlands) partnered to jointly conduct clinical trials evaluating ISA's ISA101 in combination with Regeneron's anti-PD-1 mAb cemiplimab (REGN2810, SAR439684) to treat cancer. ISA101 is an...
23:55 , Dec 18, 2017 |  BC Extra  |  Company News

Regeneron, ISA partner for HPV16-induced cancer combinations

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and ISA Pharmaceuticals B.V. (Leiden, the Netherlands) partnered to jointly conduct clinical trials evaluating ISA's ISA101 in combination with Regeneron's anti-PD-1 mAb cemiplimab (REGN2810, SAR439684) to treat cancer. ISA101 is an...
21:41 , Jul 20, 2017 |  BC Innovations  |  Product R&D

Eureka moment for TCR mimics

In the race to access the wealth of intracellular molecular targets once considered undruggable, Eureka Therapeutics Inc. is pioneering TCR -like antibodies that capitalize on the ability of TCRs to recognize tumor antigens. But the...
22:27 , Mar 16, 2017 |  BC Innovations  |  Product R&D

Neo wave

The central thesis in the increasingly hot field of neoantigens is to pick mutations from patient tumors and turn them into personalized immunotherapies. While companies are staking out their space by defining how they will...
17:13 , Dec 2, 2016 |  BC Week In Review  |  Company News

TESLA initiative launches

The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute partnered to improve algorithms used to identify cancer neoantigens. Nonprofit organization Sage Bionetworks (Seattle, Wash.) will manage bioinformatics and data analysis for the project....
00:30 , Dec 2, 2016 |  BC Extra  |  Company News

Parker Institute, CRI form neoantigen initiative

The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (New York, N.Y.) announced a partnership to improve algorithms used to identify cancer neoantigens. Nonprofit organization Sage Bionetworks (Seattle, Wash.) will manage bioinformatics and...
08:00 , Jan 4, 2016 |  BC Week In Review  |  Clinical News

HPV-SLP: Phase II started

ISA began an open-label, U.S. Phase II trial to evaluate 100 ug subcutaneous ISA101 every 3-4 weeks for up to 3 doses plus Opdivo nivolumab every 2 weeks starting on day 8 after vaccination with...